NASDAQ:DWTX Dogwood Therapeutics Q2 2026 Earnings Report $1.96 -0.03 (-1.26%) As of 01:07 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Dogwood Therapeutics EPS ResultsActual EPS-$0.34Consensus EPS -$0.14Beat/MissMissed by -$0.20One Year Ago EPSN/ADogwood Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADogwood Therapeutics Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time8:30AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Dogwood Therapeutics Earnings HeadlinesDogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Second Quarter 2026 Financial ResultsAugust 13 at 12:54 PM | finanznachrichten.deDogwood Therapeutics Announces Second Quarter 2026 Financial ResultsAugust 13 at 8:30 AM | globenewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.August 14 at 1:00 AM | Profits Run (Ad)Dogwood Therapeutics (DWTX) Projected to Announce Earnings on WednesdayAugust 11 at 2:26 AM | americanbankingnews.comDogwood Therapeutics (NASDAQ:DWTX) Stock Price Up 4.3% - What's Next?August 4, 2026 | americanbankingnews.comDogwood Therapeutics (DWTX) Stock Forecast & Price TargetJuly 21, 2026 | investing.comSee More Dogwood Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dogwood Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dogwood Therapeutics and other key companies, straight to your email. Email Address About Dogwood TherapeuticsDogwood Therapeutics (NASDAQ:DWTX) is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential. Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients. Its preclinical pipeline includes antibody and protein candidates targeting key inflammatory and fibrotic pathways. In addition to cardiovascular indications, the company is evaluating opportunities in liver and renal fibrosis, with plans to advance multiple programs into IND‐enabling studies over the coming year. Founded in 2021 and headquartered in Vancouver, British Columbia, Dogwood Therapeutics also maintains research operations in Boston, Massachusetts. The company works in collaboration with academic institutions and clinical research organizations across North America to support its development efforts. Led by an experienced management team with backgrounds in biologics discovery and cardiovascular drug development, Dogwood is positioning itself to address significant unmet needs in fibrotic disease.View Dogwood Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
